These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 18592787)

  • 61. When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer.
    Brown J; Drury L; Crane EK; Anderson WE; Tait DL; Higgins RV; Naumann RW
    J Minim Invasive Gynecol; 2019; 26(5):902-909. PubMed ID: 30240899
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter?
    Markauskas A; Mogensen O; dePont Christensen R; Jensen PT
    Int J Gynecol Cancer; 2014 Oct; 24(8):1420-8. PubMed ID: 25180461
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Impact of neoadjuvant chemotherapy on the survival of patients with stage IIIc and IV epithelial ovarian cancer].
    Yan X; An N; Jiang GQ; Gao M; Gao YN
    Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):298-301. PubMed ID: 18788637
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Neoadjuvant chemotherapy and interval debulking surgery for advanced ovarian cancer, an alternative with multiple advantages.
    Medina-Franco H; Mejía-Fernández L
    Chin Clin Oncol; 2018 Dec; 7(6):57. PubMed ID: 30180749
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Clinical significance of primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery in advanced ovarian cancer.
    Nishio S; Ushijima K
    Jpn J Clin Oncol; 2020 Apr; 50(4):379-386. PubMed ID: 32083282
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Perioperative and clinical outcomes in the management of epithelial ovarian cancer using a robotic or abdominal approach.
    Feuer GA; Lakhi N; Barker J; Salmieri S; Burrell M
    Gynecol Oncol; 2013 Dec; 131(3):520-4. PubMed ID: 24080421
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Neoadjuvant chemotherapy followed by interval cytoreductive surgery in patients with unresectable, advanced stage epithelial ovarian cancer: a single centre experience.
    Bilici A; Salepci T; Dane F; Gumus M; Ustaalioglu BB; Seker M; Salman T; Turan C; Unal O; Yaylaci M
    Arch Gynecol Obstet; 2010 Oct; 282(4):417-25. PubMed ID: 20035339
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery.
    Lee SJ; Kim BG; Lee JW; Park CS; Lee JH; Bae DS
    J Obstet Gynaecol Res; 2006 Feb; 32(1):99-106. PubMed ID: 16445534
    [TBL] [Abstract][Full Text] [Related]  

  • 69. CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy.
    Pelissier A; Bonneau C; Chéreau E; de La Motte Rouge T; Fourchotte V; Daraï E; Rouzier R
    Gynecol Oncol; 2014 Dec; 135(3):542-6. PubMed ID: 25223808
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Does modality of adjuvant chemotherapy after interval surgical debulking matter in epithelial ovarian cancer?: An exploratory analysis.
    Al Mutairi NJ; Le T
    Int J Gynecol Cancer; 2014 Mar; 24(3):461-7. PubMed ID: 24442004
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
    Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
    Am J Obstet Gynecol; 2019 Oct; 221(4):326.e1-326.e7. PubMed ID: 31082382
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Actin bundling protein fascin expression in ovarian neoplasms: comparison of histopathologic features of tumors obtained by the first and secondary cytoreduction surgeries.
    Kabukcuoglu S; Ozalp SS; Oner U; Bildirici K; Yalcin OT; Oge T; Colak E
    Eur J Gynaecol Oncol; 2006; 27(2):123-8. PubMed ID: 16620052
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.
    Zhang J; Liu N; Zhang A; Bao X
    J Obstet Gynaecol Res; 2018 Sep; 44(9):1808-1816. PubMed ID: 30019801
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ; Bristow RE; Ryu HS
    Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Outcome of Epithelial Ovarian Cancer: Time for Strategy Trials to Resolve the Problem of Optimal Timing of Surgery.
    Van de Putte G; Oben J; Prenen L; Schobbens JC; Vlasselaer J; Van Holsbeke C; Debrock G; Van Eycken P; de Jonge E
    Int J Gynecol Cancer; 2015 Jul; 25(6):993-9. PubMed ID: 25914962
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients.
    Colombo PE; Mourregot A; Fabbro M; Gutowski M; Saint-Aubert B; Quenet F; Gourgou S; Rouanet P
    Eur J Surg Oncol; 2009 Feb; 35(2):135-43. PubMed ID: 18289825
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Interval debulking surgery for advanced epithelial ovarian cancer.
    Tangjitgamol S; Manusirivithaya S; Laopaiboon M; Lumbiganon P
    Cochrane Database Syst Rev; 2008 Oct; (4):CD006014. PubMed ID: 18843699
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Negative peritoneal washing cytology during interval debulking surgery predicts overall survival after neoadjuvant chemotherapy for ovarian cancer.
    Iura A; Takita M; Kawano A; Imai K; Konnai K; Onose R; Kato H
    J Gynecol Oncol; 2018 Sep; 29(5):e70. PubMed ID: 30022634
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.
    Morrison J; Swanton A; Collins S; Kehoe S
    Cochrane Database Syst Rev; 2007 Oct; (4):CD005343. PubMed ID: 17943850
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical outcomes of neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian carcinoma.
    Giannopoulos T; Butler-Manuel S; Taylor A; Ngeh N; Thomas H
    Eur J Gynaecol Oncol; 2006; 27(1):25-8. PubMed ID: 16550963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.